Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are rising Tuesday. Traders seemingly position ahead of the FDA’s pending decision on its Duchenne muscular dystrophy therapy, deramiocel. Here’s what you should know.
- Capricor Therapeutics stock is showing upward movement. What’s pushing CAPR stock higher?
Capricor Stock Rises Ahead of FDA Decision
Capricor turns cells and exosomes into treatments for rare diseases, and its lead drug, deramiocel, is aimed at Duchenne muscular dystrophy, a progressive muscle-wasting illness. Regulators are weighing the company’s Biologics License Application.
Capricor said in a Nov. 9 press release that its Biologics License Application, the formal request for approval, remains under FDA review. The agency has set Nov. 22, 2026, as its PDUFA target date to rule.
Investors are watching how that ruling treats a label built around upper-limb function and the Phase 3 HOPE-3 data.
HOPE-3 Results and New Cardiac Data
In HOPE-3, 106 patients were randomly assigned to deramiocel or a placebo for a year, and the drug achieved its main goal of better upper-limb function. The leading follow-up measure, heart pumping function across everyone in the study, rose 1.8 percentage points but did not clear the bar for statistical significance, at a p-value of 0.09.
Patients with cardiomyopathy, a subgroup defined in advance, did better, with heart function up 2.8 percentage points over placebo and 3.0 fewer new scarred heart segments on MRI. Capricor cautioned that those subgroup and scarring p-values are nominal, since they ignore the many comparisons being made.
The company also matched treated patients to others from natural history records, an analysis done after the fact without randomization. It found heart function up 2.3 percentage points for all patients and 2.9 fewer new scarred segments. The American Heart Association gave the cardiac findings a pediatric cardiology research award on Nov. 7, and The Lancet has published the one-year results.
The data could support the stock by strengthening the drug’s FDA case, highlighting potential cardiac benefits in a disease with no approved heart treatment and boosting confidence through recognition from the AHA and The Lancet. However, risks remain after a missed secondary endpoint and reliance on nominal p-values.
CAPR Shares Are Moving Higher
CAPR Price Action: Capricor shares were up 2.29% at $8.49 at the time of publication on Tuesday, according to Benzinga Pro.
Image: Pavel Kapysh/Shutterstock
